Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): A trial of the Eastern Cooperative Oncology Group

Urologic Oncology: Seminars and Original Investigations

Volumn 27, Issue 5, 2009, Pages 496-501

  Ignatoff, Jeffrey M ^a   Chen, Yu Hui ^b   Greenberg, Richard Evan ^c   Pow Sang, Julio M ^d   Messing, Edward M ^e   Wilding, George ^f  

^a NORTHWESTERN UNIVERSITY   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c FOX CHASE CANCER CENTER   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF ROCHESTER   (United States)

^f UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

AD32; Bladder; Carcinoma in situ; Intravesical; Superficial transitional cell carcinoma; Urothelial carcinoma

Indexed keywords

BCG VACCINE; VALRUBICIN;

ABDOMINAL CRAMP; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BLADDER CRAMP; BLADDER DISEASE; BLEEDING; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOMA IN SITU; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG FEVER; DRUG MEGADOSE; DRUG TREATMENT FAILURE; DYSURIA; EDEMA; FATIGUE; FEMALE; FOLLOW UP; GRANULOCYTOPENIA; HEMORRHAGIC CYSTITIS; HUMAN; INFECTION; LEUKOPENIA; LIVER DISEASE; MALE; MYALGIA; NAUSEA; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SKIN DISEASE; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; URINARY FREQUENCY; URINE INCONTINENCE; URINE RETENTION; UROGENITAL TRACT CANCER; UROGENITAL TRACT CARCINOMA; UROGENITAL TRACT DISEASE; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

ADMINISTRATION, INTRAVESICAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BCG VACCINE; CARCINOMA IN SITU; CARCINOMA, TRANSITIONAL CELL; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; URINARY BLADDER NEOPLASMS;

EID: 69249141487     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2008.05.004     Document Type: Article

References (27)

1. Dalbagni G. The management of superficial bladder cancer. Nat Clin Pract Urol 4 (2007) 254-260
2. Klein E.A., Rogatko A., and Herr H.W. Management of local bacillus Calmette-Guerin failures in superficial bladder cancer. J Urol 147 (1992) 601-605
3. Greenberg R., O'Dwyer P., Patterson L., et al. Intravesical AD 32 (N-trifluoroacetyladriamycin-14-valerate) in the treatment of patients with refractory bladder carcinoma-clinical efficacy, pharmacology, and safety. J Urol 153 (1995) 233A [Abstract]
4. Greenberg R.E., Bahnson R.R., Wood D., et al. Initial report on intravesical administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder. Urology 49 (1997) 471-475
5. Patterson A.L., Greenberg R.E., Weems L., et al. Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer. Urology 56 (2000) 232-235
6. Lamm D.L., Riggs D.R., Traynelis C.L., et al. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J Urol 153 (1995) 1444-1450
7. Perabo F.G., and Muller S.C. Current and new strategies in immunotherapy for superficial bladder cancer. Urology 64 (2004) 409-421
8. Lamm D.L. Bacillus Calmette-Guerin immunotherapy for bladder cancer. J Urol 134 (1985) 40-47
9. Durek C., Richter E., Basteck A., et al. The fate of bacillus Calmette-Guerin after intravesical instillation. J Urol 165 (2001) 1765-1768
10. Rischmann P., Desgrandchamps F., Malavaud B., et al. BCG intravesical instillations: Recommendations for side-effects management. Eur Urol 37 Suppl 1 (2000) 33-36
11. Carroll P.R. Urothelial Cancers: Cancers of the renal pelvis, ureter, and bladder. In: Tanagho E.A., and McAnich J. (Eds). Smith's General Urology (1992), Lange Medical Books, Norwalk, CT
12. Nadler R.B., Catalona W.J., Hudson M.A., et al. Durability of the tumor-free response for intravesical bacillus Calmette-Guerin therapy. J Urol 152 (1994) 367-373
13. Herr H.W., Wartinger D.D., Fair W.R., et al. Bacillus Calmette-Guerin therapy for superficial bladder cancer: A 10-year follow-up. J Urol 147 (1992) 1020-1023
14. Herr H.W. Progression of Stage T1 bladder tumors after intravesical bacillus Calmette-Guerin. J Urol 145 (1991) 40-43
15. Raj G.V., Herr H., Serio A.M., et al. Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. J Urol 177 (2007) 1283-1286
16. Dalbagni G. The management of superficial bladder cancer. Nat Clin Pract Urol 4 (2007) 254-260
17. Shintani Y., Sawada Y., Inagaki T., et al. Intravesical instillation therapy with bacillus Calmette-Guerin for superficial bladder cancer: Study of the mechanism of bacillus Calmette-Guerin immunotherapy. Int J Urol 14 (2007) 140-146
18. Altay B., Girgin C., Kefi A., et al. The best management of superficial bladder tumors: Comparing TUR alone vs. TUR combined with intravesical chemotherapy modalities?. Int Urol Nephrol 32 (2000) 53-58
19. Amling C.L. Diagnosis and management of superficial bladder cancer. Curr Probl Cancer 25 (2001) 219-278
20. Oosterlinck W. Guidelines on diagnosis and treatment of superficial bladder cancer. Minerva Urol Nefrol 56 (2004) 65-72
21. Lamm D.L. Superficial bladder cancer. Curr Treat Options Oncol 3 (2002) 403-411
22. Israel M., Modest E.J., and Frei III E. N-trifluoroacetyladriamycin-14-valerate, an analog with greater experimental antitumor activity and less toxicity than adriamycin. Cancer Res 35 (1975) 1365-1368
23. Israel M, Khetarpal VK. Tissue distribution and metabolism of N-trifluoroacetyladriamycin-14-valerate (AD 32) compared with adriamycin in mice bearing established Lewis lung carcinomas tissue distribution and metabolism of N-trifluoroacetyladriamycin-14-valerate (AD 32) compared with adriamycin in mice bearing established Lewis lung carcinomas. Proceedings of the 13th International Congress of Chemotherapy, Vienna, Austria, Aug 28-Sept 2, 1983 [Abstract].
24. Blum R., Garnick M., Israel M., et al. Preclinical Rationale and Phase I Clinical Trials of the Adriamycin Analog AD 32. In: Carter S., Sakurai Y., and Umezawa H. (Eds). Recent Results in Cancer Research. New Drugs in Cancer Chemotherapy (1981), Springer Verlag, New York
25. Greenberg R.E., O'Dwyer P.J., and Patterson A.L. Intravesical AD 32 (N-trifluoroacetyladriamycin-14-valerate) in the treatment of patients with refractory bladder carcinoma-clinical efficacy, pharmacology, and safety. J Urol 153 (1995) 233a
26. Blum R.H., Garnick M.B., Israel M., et al. Initial clinical evaluation of N-trifluoroacetyladriamycin-14-valerate (AD-32), an adriamycin analog. Cancer Treat Rep 63 (1979) 919-923
27. Garnick M., Griffin J., Sack M., et al. Phase II Evaluation of Ntrifluoroacetyladriamycin-14-valerate (AD 32). In: Muggia F., Young C., and Carter S. (Eds). Anthracycline Antibiotics in Cancer Therapy (1982), Martinus Nijhoff, The Netherlands